Celsion Corporation (NASDAQ:CLSN) down 6% in a week. The company has announced that EVP and Chief Scientific Officer Khursheed Anwer will present Celsion’s GEN-1 interleukin 12 monotherapy during the Cytokine-Based Cancer Immunotherapies Summit taking place from November 30 to December 2, 2021, in Boston.
Trading Data
On Monday, CLSN stock went up 0.26% at $0.89 with more than 920K shares, compared to its average volume of 956K shares. The stock has moved within a range of $0.8718 – 0.9000 after opening the trade at $0.8947.
GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit
In addition, Anwer will participate in two-panel discussions. During the presentation, Anwer will discuss how local IL-12 delivery without considerable systemic toxicity is possible through a non-viral gene therapy model involving IL-12 plasmid administration with GEN-1 (synthetic DNA delivery).
Also, Anwer will discuss how the weekly intraperitoneal GEN-1 administration results in durable IL10 and IFGN-g increases and the significance of repeated weekly GEN-1 administration combined with standard chemo remodels the tumor immune environment leading to immune stimulation rather than immune suppression. Celsion CEO and President Michael Tardugno said that Dr. Anwer’s panel discussions and presentation would demonstrate the strength of the company’s GEN-1 immunotherapy to a leading immunologist in the country. Therefore CLSN is worth watching.
Key Quote
“Dr. Anwer’s presentation and panel discussions will highlight the strength of our GEN-1 immunotherapy program to some of the nation’s leading immunologists,” said Michael H. Tardugno, chairman, president and chief executive officer of Celsion. “We look forward to interacting with attendees at one of the first in-person medical conferences we will be attending since the COVID-19 pandemic began.”
Technical Data
CLSN stock is trading below the 20-Day and 50-Day Moving averages of $0.93 and $0.98 respectively. Moreover, the stock is trading below 200-Day moving average of $1.29 The stock is down 18% in the past 3-month.
